Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).

@article{citeulike:451546, abstract = {This report updates the last recommendations by the Advisory Committee on Immunization Practices (ACIP) concerning pneumococcal polysaccharide vaccine (MMWR 1989;38:64-8, 73-6). ACIP recommends that the vaccine be used more extensively and administered to all persons in the following groups: a) persons aged > or = 65 years, b) immunocompetent persons aged > or = to 2 years who are at increased risk for illness and death associated with pneumococcal disease because of chronic illness, c) persons aged > or = 2 years with functional or anatomic asplenia, d) persons aged > or = 2 years living in environments in which the risk for disease is high, and e) immunocompromised persons aged > or = 2 years who are at high risk for infection. This report contains updated information regarding a) antimicrobial resistance among pneumococci, b) vaccine effectiveness and cost-effectiveness, c) indications for vaccination, d) guidelines for revaccination, e) strategies for improving delivery of vaccine, and f) development of pneumococcal conjugate vaccine.}, citeulike-article-id = {451546}, issn = {1057-5987}, journal = {MMWR Recomm Rep}, keywords = {cdc, guidelines, pneumovax}, month = {April}, number = {RR-8}, pages = {1--24}, posted-at = {2005-12-27 22:47:52}, priority = {5}, title = {Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).}, url = {http://view.ncbi.nlm.nih.gov/pubmed/9132580}, volume = {46}, year = {1997} }

TY - JOUR ID - citeulike:451546 L3 - citeulike-article-id:451546 N2 - This report updates the last recommendations by the Advisory Committee on Immunization Practices (ACIP) concerning pneumococcal polysaccharide vaccine (MMWR 1989;38:64-8, 73-6). ACIP recommends that the vaccine be used more extensively and administered to all persons in the following groups: a) persons aged > or = 65 years, b) immunocompetent persons aged > or = to 2 years who are at increased risk for illness and death associated with pneumococcal disease because of chronic illness, c) persons aged > or = 2 years with functional or anatomic asplenia, d) persons aged > or = 2 years living in environments in which the risk for disease is high, and e) immunocompromised persons aged > or = 2 years who are at high risk for infection. This report contains updated information regarding a) antimicrobial resistance among pneumococci, b) vaccine effectiveness and cost-effectiveness, c) indications for vaccination, d) guidelines for revaccination, e) strategies for improving delivery of vaccine, and f) development of pneumococcal conjugate vaccine. IS - RR-8 JF - MMWR Recomm Rep SN - 1057-5987 EP - 24 TI - Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). VL - 46 SP - 1 KW - cdc KW - guidelines KW - pneumovax PY - 1997/04/04/ UR - http://view.ncbi.nlm.nih.gov/pubmed/9132580 ER -